These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Problems of antineoplastic chemotherapy of pancreatic cancer]. Matthias M; Wolff H Zentralbl Chir; 1987; 112(21):1322-36. PubMed ID: 3324556 [TBL] [Abstract][Full Text] [Related]
5. Current status of chemotherapy in metastatic pancreatic cancer. Wils JA Anticancer Res; 1989; 9(4):1027-31. PubMed ID: 2683988 [TBL] [Abstract][Full Text] [Related]
6. A review of systemic therapy for advanced pancreatic cancer. El-Rayes BF; Philip PA Clin Adv Hematol Oncol; 2003 Jul; 1(7):430-4. PubMed ID: 16258429 [TBL] [Abstract][Full Text] [Related]
7. FOLFIRINOX: a new standard treatment for advanced pancreatic cancer? Kim R Lancet Oncol; 2011 Jan; 12(1):8-9. PubMed ID: 21050812 [No Abstract] [Full Text] [Related]
8. Role of second-line chemotherapy in advanced pancreatic cancer and its influence on phase II/III study results. Teo M; McDermott RS Ann Oncol; 2013 Sep; 24(9):2462-3. PubMed ID: 23986547 [No Abstract] [Full Text] [Related]
9. [Second-line chemotherapy for advanced pancreatic cancer]. Sato A; Saito K; Takahata T Gan To Kagaku Ryoho; 2015 Apr; 42(4):403-7. PubMed ID: 25963687 [TBL] [Abstract][Full Text] [Related]
20. Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer? Sasaki Y; Hamada K; Kaneta T; Takahashi T; Kubota Y; Ishida H; Ichikawa W Cancer Sci; 2015 Aug; 106(8):1100. PubMed ID: 26268893 [No Abstract] [Full Text] [Related] [Next] [New Search]